I-Corps: Single-domain antibody platform to develop cancer immunotherapies for the treatment of both canine and human cancers

这个i-Corps项目的更广泛的影响/商业化潜力是开发和翻译一个治疗犬癌和人类癌症的药物发现平台。这项拟议的技术定义了利用基于免疫的癌症疗法的能力来靶向和根除癌症的要求，药物平台可能被操纵以创造新的和强大的疗法。开发基于免疫的癌症疗法可能会产生一些成本效益高、安全的疗法，这些疗法很容易给患者使用，可能会产生重大的商业影响。这项拟议的技术有望通过将狗作为临床研究的动物模型来转换对癌症进展的理解。这种方法将是犬类疗法的第一次，预计将影响人类癌症疗法的发展。这个i-Corps项目基于开发单域抗体平台，以开发用于治疗犬癌和人类癌症的癌症免疫疗法。基于单域抗体平台的癌症免疫疗法尚未被批准用于人类，建议的犬类药物的开发可能为了解这类药物在适当疾病环境中的药理学行为提供有价值的见解。此外，将单域抗体与其他癌症治疗药物物理结合，可能会增加一种免疫分子用于对抗癌症生长的新方法。这项拟议的技术有可能为所有类型的患者带来量身定做的癌症疗法。因此，这一最先进的技术进步有可能迅速为所有癌症患者带来新的、有效的产品，并具有显著的商业和社会影响潜力。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercialization potential of this I-Corps project is the development and translation of a drug discovery platform for the treatment of both canine and human cancers. The proposed technology defines the requirements for harnessing the ability of immune-based cancer therapies to target and eradicate cancer with a drug platform that may be manipulated to create new and powerful therapies. Developing immune-based cancer therapies may result in the production of a number of cost effective and safe treatments that may be easily administered to patients, potentially making a significant commercial impact. The proposed technology is expected to translate the understanding of cancer progression using the dog as an animal model for clinical investigations. This approach would be a first for canine therapies and is expected to impact development of human cancer therapeutics.This I-Corps project is based on the development of a single-domain antibody platform to develop cancer immunotherapies for the treatment of both canine and human cancers. Cancer immunotherapies based on a single-domain antibody platform have yet to be approved for human use and the development of the proposed canine agents may provide valuable insight into the pharmacologic behavior of this type of agent in the appropriate disease setting. In addition, physically combining single-domain antibodies with other cancer treatment agents, may add a novel way immune molecules may be used to fight cancer growth. The proposed technology has the potential to result in tailored cancer therapies for patients of all types. Thus, this advancement of the state-of-the-art has the potential to quickly bring novel, effective products to all cancer-patients, with marked potential for high commercial and societal impact.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.